https://www.selleckchem.com/products/cx-5461.html
PURPOSE The histone-methyl transferase EZH2, catalytic subunit of the PRC2 complex involved in transcriptional regulation is mutated in approximately 25% of germinal center B-cell lymphomas. Aberrant proliferative dependency on EZH2 activity can be targeted by the orally available EZH2 inhibitor tazemetostat (EPZ-6438). We report the results of the phase Ib tazemetostat plus R-CHOP combination (NCT02889523), in patients 60-80 years with newly diagnosed diffuse large B cell lymphoma. EXPERIMENTAL DESIGN The primary objective of this dose
Beğen
Yorum Yap
Paylaş
